UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 180 filers reported holding UNIQURE NV in Q2 2023. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $6,658,626 | +88740.9% | 330,617 | 0.0% | 0.02% | -11.1% |
| Q4 2022 | $7,495 | -99.9% | 330,617 | 0.0% | 0.03% | +12.5% |
| Q3 2022 | $6,202,000 | -25.6% | 330,617 | -26.0% | 0.02% | -22.6% |
| Q2 2022 | $8,332,000 | +2.7% | 447,014 | -0.4% | 0.03% | +34.8% |
| Q1 2022 | $8,113,000 | +172.2% | 448,985 | +382.1% | 0.02% | +130.0% |
| Q3 2021 | $2,981,000 | -67.3% | 93,129 | -68.5% | 0.01% | -67.7% |
| Q2 2021 | $9,109,000 | +1651.7% | 295,749 | +1996.3% | 0.03% | +933.3% |
| Q3 2020 | $520,000 | -79.6% | 14,108 | -73.7% | 0.00% | -85.0% |
| Q1 2020 | $2,544,000 | +352.7% | 53,607 | +583.6% | 0.02% | +400.0% |
| Q4 2019 | $562,000 | -81.7% | 7,842 | -90.0% | 0.00% | -81.0% |
| Q3 2019 | $3,076,000 | +517.7% | 78,153 | +836.5% | 0.02% | +320.0% |
| Q1 2019 | $498,000 | – | 8,345 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
| Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
| 683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
| PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
| Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
| Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
| Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
| Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
| Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |